Oramed Pharmaceuticals (Oramed Pharmaceuticals) EV-to-Revenue : -10.74 (As of Apr. 25, 2024)

Oramed Pharmaceuticals EV-to-Revenue Chart

Oramed Pharmaceuticals Annual Data
	Trend	Aug14	Aug15	Aug16	Aug17	Aug18	Aug19	Aug20	Aug21	Dec22	Dec23
EV-to-Revenue		Get a 7-Day Free Trial					9.41	15.79	222.61	118.56	-13.56

Oramed Pharmaceuticals Quarterly Data
	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial															118.56	-24.64	-2.36	2.57	-13.56

Competitive Comparison of Oramed Pharmaceuticals's EV-to-Revenue

For the Biotechnology subindustry, Oramed Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oramed Pharmaceuticals's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oramed Pharmaceuticals's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Oramed Pharmaceuticals's EV-to-Revenue falls into.

Oramed Pharmaceuticals EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Oramed Pharmaceuticals's EV-to-Revenue for today is calculated as:

Oramed Pharmaceuticals's current Enterprise Value is $-14.40 Mil.
Oramed Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.34 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oramed Pharmaceuticals  (NAS:ORMP) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Oramed Pharmaceuticals's PS Ratiofor today is calculated as:

Oramed Pharmaceuticals's share price for today is $2.37.
Oramed Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.03.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oramed Pharmaceuticals EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Oramed Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Oramed Pharmaceuticals (Oramed Pharmaceuticals) Business Description